Congenital Hyperinsulinism (HI) includes many subtypes that all cause hypoglycemia due to the overproduction of insulin, which can lead to permanent brain damage or death. The consequences of HI are preventable – however, HI is often overlooked, misdiagnosed, or even when detected, mistreated. We are seeking applications for an innovative clinical or pre-clinical study that has the potential to benefit all types of HI and lead to: (1) a better understanding of the patient experience and/or natural history of HI; (2) novel or more effective diagnostics; (3) a quality of life improvement for those affected by HI; or (4) enhanced management or new treatments for HI. Multi-institution or multi-center collaboration is highly encouraged. The HI Global Registry (HIGR) is a global patient-powered congenital hyperinsulinism patient registry and consists of a series of thirteen surveys made up of questions related to a patient’s HI experience over their lifetime (https://www.higlobalregistry.org/). HIGR must be used as a data source or a tool to collect study data. If the project proposes collecting new data as a sub-study to HIGR on the IamRare platform, $11,000 of the grant funding must be allocated for platform implementation costs. If the project proposes to use existing HIGR surveys as a data source, there is no implementation fee. One grant of $73,190 is made possible by Team CHIbra and Congenital Hyperinsulinism International.